About the Company
headquartered in canton, massachusetts, organogenesis inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
1073
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ORGO News
Organogenesis (ORGO) Q4 2023 Earnings Call Transcript
Welcome, ladies and gentlemen, to the fourth quarter and fiscal year 2023 earnings conference call for Organogenesis Holding, ...
Organogenesis Holdings Inc (ORGO) Faces Revenue Decline in Q4 and FY 2023, Aims for Growth in 2024
Decreased by 14% in Q4 2023 and 4% for FY 2023 compared to the previous year. Net Income: Dropped significantly to $4.9 ...
Organogenesis Holdings Inc. Cl A
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
Anika Therapeutics to reduce workforce by 9%
Anika Therapeutics plans to reduce spending for 2024 and its workforce by 9%, leading to expected annual savings of $10M.
Future Market Insights Announces Groundbreaking Entry into the Thriving Collagen Skin Matrix Market is projected to achieve US$ 988.2 Million by 2033
Future Market Insights, a leading provider of market research and consulting services, is proud to announce its pioneering entry into the rapidly expanding global collagen skin matrix market. This ...
Entrada Therapeutics GAAP EPS of -$0.29 beats by $0.81, revenue of $41.85M
Q4 GAAP EPS of -$0.29 beats by $0.81. Revenue of $41.85M. $352 million in cash, cash equivalents and marketable securities as of December 31, 2023 ...
Buy Rating Affirmed for enGene Holdings Amid Promising Early-Stage Data and Strong Market Prospects
Gene Holdings (ENGN) has received a new Buy rating, initiated by Morgan Stanley analyst, Jeffrey Hung. Jeffrey Hung has given his Buy rating ...
Loading the latest forecasts...